CoChat

Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Background: Preclinical Alzheimer’s disease (AD) is defined by cerebral amyloid-β positivity (Aβ+) in cognitively normal (CN) older adults. Objective: To estimate the risk of progression to the symptomatic stages of AD due to PET Aβ+ and the extent that progression was influenced by other demographic, genetic, and clinical characteristics in a large prospective study. Methods: Fine-Gray subdistribution modeling was used to examine the risk of progression from CN to MCI/dementia due to Aβ+, APOE ɛ4 carriage, and their interaction in the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging CN cohort ( n = 599) over 8 years. Results: 17.7% Aβ+ and 8.1% Aβ–progressed over 8 years (OR: 2.43). Risk of progression for Aβ+ was 65–104% greater than Aβ–. Aβ+ APOE ɛ4 carriers were at 348% greater risk than all other participants. Significant risk factors of progression in Aβ+ were age (HR: 1.05), PET SUVR (HR: 2.49) and APOE ɛ4 carriage (HR: 2.63); only age was a significant risk factor in Aβ–(HR: 1.09). Aβ–progressors were not near the threshold for Aβ+. These relationships were not moderated by hypertension, diabetes, obesity, or stroke/TIA. Conclusion: Aβ+ is an important prognostic marker for progression from CN to MCI/dementia in older adults and APOE ɛ4 carriage provides further predictive value in the presence of Aβ+. These data suggest that Aβ-associated clinical progression is consistent with clinical-pathological models of AD, whereas progression in the absence of elevated Aβ deposition may be the result of neuropathological processes other than AD that accumulate with age.

Overview

Integrity signals

Registry

Crossref · 10.3233/jad-180507

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Lim YY, 2018, JAMA Neurol, 3052, 1

Cited by

See all 31

Metadata

Authors
Dang, C., Harrington, K. D., Lim, Y. Y., Ames, D., Hassenstab, J., Laws, S. M., Yassi, N., Hickey, M., Rainey-Smith, S., Robertson, J., Sohrabi, H. R., Salvado, O., Weinborn, M., Villemagne, V. L., Rowe, C. C., Masters, C. L., Maruff, P., & for the AIBL Research Group
Affiliations
  • The University of Melbourne (AU)
  • Washington University in St. Louis (US)
  • Edith Cowan University (AU)
  • The Royal Melbourne Hospital (AU)
  • Centre of Excellence for Alzheimer’s Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
  • Commonwealth Scientific and Industrial Research Organisation (AU)
Corresponding author
Dang, Christa
Venue
Journal of Alzheimer’s Disease
Published
2018-08-22
Volume
65
Issue
4
Pages
1313-1325
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2888422974
Cited by
31
References
45
Citations by year
2026: 2 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 2
FWCI
2.55
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Murdoch University Research Portal (submittedVersion)
  • Edith Cowan University Research Online (Edith Cowan University) (submittedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
cerebral amyloid-beta, preclinical Alzheimer's disease
MeSH terms
Aged, Aged, 80 and over, Aging, Cerebral Cortex, Dementia, Female, Humans, Longitudinal Studies, Male, Middle Aged, Survival Analysis, Amyloid beta-Peptides, Disease Progression, Statistics, Nonparametric, Positron-Emission Tomography, Apolipoprotein E4, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.